The GLP-1 receptor agonist market is witnessing a significant surge in demand worldwide, driven by increasing prevalence of type 2 diabetes, rising awareness of novel antidiabetic therapies, and a growing focus on weight management. With the escalating global health burden associated with metabolic disorders, glucagon-like peptide-1 receptor agonists are emerging as a preferred therapeutic...